|Treatments:||Chemotherapy, Biologic therapy||Hospital:||Leicester Royal Infirmary|
Patients: This phase IB study involved thirty-five patients with advanced colorectal cancer, 18 of which were men, 17 were women. The median age was 63 years. Twelve of the patients had prior chemotherapy
Treatment: All patients received FOLFOX4 ( chemotherapy - oxaliplatin/5-fluorouracil (5-FU) and folinic acid - leucovorin) and the oral angiogenesis inhibitor - PTK787/ZK.
Toxicity: Grade 4 vomiting, dizziness, ataxia, and neutropenia toxicities were reported. The most common toxicities were nausea, diarrhea, fatigue/lethargy, and vomiting.
Results: The estimated median progression free survival was 11.4 months.
Support: This study was supported by Novartis Pharmaceuticals and Schering, which partnered to develop and market PTK787.
Correspondence: Dr. A. L. Thomas